Opendata, web and dolomites

CAtALySt SIGNED

NeurescueTM: Computer- controlled aortic occlusion device for the treatment of cardiac arrest

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 CAtALySt project word cloud

Explore the words cloud of the CAtALySt project. It provides you a very rough idea of what is the project "CAtALySt" about.

neurescue    medical    introduction    post    worldwide    million    total    incidence    validation    10    public    brain    assistance    damage    health    aortic    combines    clinical    heart    commercial    vital    generation    with    paris    arrests    probability    patients    accurate    survival    predicted    critical    projected    adoption    severe    radically    broad    safe    neurescuetm    accuracy    hospital    organs    run    game    inside    89    market    de    resuscitation    marking    standard    profitable    denmark    tissue    aps    competitive    necker    synergy    roll    position    occlusion    proposes    data    function    window    time    proposition    patient    portable    device    outside    rates    episodes    sudden    emergency    algorithm    building    light    company    2030    premises    portability    preservation    demonstration    chu    price    united    changing    france    neur    surpass    234m    2020    sca    germany    odense    normal    aggregated    unrivalled    sensor    23    samu    computer    holding    gathering    perfusion    intervention    works    aorta    blood    below    university    barriers    ready    business    roject    solution    ce    burden    pressure    cardiac    rate    catalyst    revenue    back    40   

Project "CAtALySt" data sheet

The following table provides information about the project.

Coordinator
NEURESCUE APS 

Organization address
address: NJALSGADE 76
city: KOBENHAVN
postcode: 2300
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Denmark [DK]
 Project website https://www.neurescue.com/home-eu/
 Total cost 2˙331˙787 €
 EC max contribution 1˙632˙251 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2018
 Duration (year-month-day) from 2018-08-01   to  2021-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    NEURESCUE APS DK (KOBENHAVN) coordinator 1˙632˙251.00

Map

 Project objective

With a worldwide incidence expected to increase from 9,23 million cases by 2020 to 10,89 million cases by 2030, Sudden Cardiac Arrests (SCA) episodes are today recognized as a public health problem leading to severe brain tissue damage with survival rates below 10%. Neurescue Aps (NEUR) proposes to address the SCA burden by bringing to light a game changing solution - NeurescueTM – capable of extending the critical time window necessary to bring a SCA patient back to normal heart function, and therefore holding the potential to radically improve the emergency assistance provided to SCA patients, allowing for 20- 40% of increase in the survival rate of SCA patients. Due to an algorithm-run sensor technology which enables a safe and accurate computer-controlled aortic occlusion, NeurescueTM is a portable medical device that, not only increases the blood perfusion pressure necessary for vital organs preservation (i.e. brain and heart), but also works in synergy with standard resuscitation procedures increasing their probability of success. NeurescueTM is the only device in the market that combines portability with the accuracy required for a safe medical intervention (i.e. aorta occlusion) to SCA patients both inside and outside the hospital premises. With a price-competitive technology and with an unrivalled value proposition, NEUR is in a strong position to build a profitable business. Building on the project activities, NeurescueTM the device is projected to be ready for commercial roll-out by 2020 with a predicted total aggregated revenue for the company of over €234M throughout the 5 years post- roject. CAtALySt project aims to surpass the main market barriers associated with the market introduction of NeurescueTM, namely gathering data for CE-marking and broad clinical demonstration for market awareness and to ensure end-user medical adoption. Clinical validation will be held at Odense University Hospital in Denmark, and further clinical evidence generation at Hospital SAMU de Paris CHU Necker in France, a leading university hospital in Germany, and a leading university hospital in the United States.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CATALYST" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CATALYST" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Savesight (2020)

Contact lens embedded sensor for ocular hypertension and glaucoma monitoring

Read More  

Path Feel (2019)

Insoles for Neuropathy and Balance Issues

Read More  

ALR4000 (2019)

Automated LCD Recycling series 4000

Read More